GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (STU:26CA) » Definitions » Total Receivables

ImmunityBio (STU:26CA) Total Receivables : €1.97 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Total Receivables?

ImmunityBio's Total Receivables for the quarter that ended in Mar. 2024 was €1.97 Mil.


ImmunityBio Total Receivables Historical Data

The historical data trend for ImmunityBio's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Total Receivables Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
- 1.65 1.18 1.78 2.91

ImmunityBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 3.03 2.18 2.91 1.97

ImmunityBio Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


ImmunityBio Total Receivables Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunityBio (STU:26CA) Business Description

Traded in Other Exchanges
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.

ImmunityBio (STU:26CA) Headlines

No Headlines